Gagnon Securities LLC raised its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR – Free Report) by 14.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,826,604 shares of the medical instruments supplier’s stock after purchasing an additional 234,457 shares during the quarter. OraSure Technologies accounts for approximately 1.2% of Gagnon Securities LLC’s holdings, making the stock its 28th biggest position. Gagnon Securities LLC owned about 2.65% of OraSure Technologies worth $7,160,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in the company. Altai Capital Management L.P. bought a new stake in OraSure Technologies during the second quarter valued at about $16,118,000. BlackRock Inc. bought a new position in shares of OraSure Technologies in the second quarter worth about $27,905,000. Cannell Capital LLC purchased a new position in shares of OraSure Technologies during the 2nd quarter valued at about $6,366,289. Yorkville Advisors Global LP purchased a new position in shares of OraSure Technologies during the 1st quarter valued at about $1,905,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of OraSure Technologies during the 2nd quarter valued at about $926,000. 93.50% of the stock is currently owned by institutional investors.
OraSure Technologies Price Performance
OSUR stock opened at $3.56 on Thursday. OraSure Technologies, Inc. has a 1-year low of $2.08 and a 1-year high of $4.58. The company has a market capitalization of $245.53 million, a price-to-earnings ratio of -5.16 and a beta of 1.08. The business has a 50 day simple moving average of $3.72 and a two-hundred day simple moving average of $3.54.
OraSure Technologies (NASDAQ:OSUR – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The medical instruments supplier reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.05. The business had revenue of $30.91 million during the quarter, compared to analyst estimates of $31.00 million. OraSure Technologies had a negative net margin of 41.73% and a negative return on equity of 19.81%. Sell-side analysts anticipate that OraSure Technologies, Inc. will post -0.96 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on OSUR shares. Zacks Research raised shares of OraSure Technologies to a “hold” rating in a report on Friday, October 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OraSure Technologies in a report on Tuesday, September 1st. Wall Street Zen upgraded shares of OraSure Technologies from a “sell” rating to a “hold” rating in a research report on Monday, August 10th. Finally, Craig Hallum raised shares of OraSure Technologies to a “strong-buy” rating in a research note on Friday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold”.
Get Our Latest Research Report on OraSure Technologies
Top OraSure Technologies Stories
Here are a few of the latest stories about OSUR:
- Positive Sentiment: The company reached an agreement with activist investor Altai Capital, reducing the prospect of a costly proxy battle and easing a source of uncertainty for investors. OraSure activist agreement
- Neutral Sentiment: OraSure is exploring inorganic opportunities and global growth avenues. These could broaden its business, but no specific transaction or near-term financial contribution was reported. OraSure seeks inorganic opportunities
- Negative Sentiment: Management forecast Q4 revenue of $30 million-$32 million and FY 2026 revenue of $120.4 million, both slightly below analyst consensus of $31.8 million and $121.5 million, respectively. The company also pushed its expected cash-flow break-even timing to the second half of 2027, which could weigh on expectations for profitability and cash use. OraSure Q4 outlook and break-even timing
About OraSure Technologies
OraSure Technologies, Inc. develops, manufactures and markets diagnostic products and specimen-collection technologies used by healthcare providers, laboratories, researchers and consumers. The company focuses on making testing more accessible through products that support decentralized, point-of-care and at-home testing, as well as laboratory-based molecular and diagnostic workflows. Its portfolio has included the OraQuick line of rapid diagnostic tests, including oral-fluid tests for HIV and hepatitis C, along with other infectious-disease testing products.
See Also
- Five stocks we like better than OraSure Technologies
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR – Free Report).
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
